Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology

08 Jun, 2016, 08:25 ET from Chelmsford Park SA

NEW YORK, June 8, 2016 /PRNewswire/ --

On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:

http://www.activewallst.com/register/

Spain, Barcelona headquartered biopharma Company, Grifols S.A.'s stock finished Monday's session 0.76% higher at $17.30 with a total volume of 1.60 million shares traded. Over the last one month and the previous three months, the Company's shares have gained 17.13% and 13.25%, respectively. Additionally, the Company's stock has advanced 15.79% in the past one year. The stock is trading above its 50-day and 200-day moving averages by 12.23% and 10.48%, respectively. Grifols' stock traded at a PE ratio of 40.23 and has a Relative Strength Index (RSI) of 78.79. Sign up and read the free notes on GRFS at:

http://www.activewallst.com/register/

Connecticut headquartered biopharma Company, Achillion Pharmaceuticals Inc.'s stock lost 3.55% to close the day at $9.51 with a total volume of 1.31 million shares traded. The Company's shares have gained 20.08% in the last one month and 27.14% in the previous three months. Furthermore, the stock has advanced 4.85% in the past one year. The stock is trading 12.50% and 15.59% above its 50-day and 200-day moving averages, respectively. Additionally, Achillion Pharmaceuticals' stock has an RSI of 63.35. The complimentary notes on ACHN can be downloaded in PDF format at:

http://www.activewallst.com/register/

On Monday, shares in Jazz Pharmaceuticals PLC ended the session 0.46% lower at $154.91 with a total volume of 672,988 shares traded. Shares of the Company traded at a PE ratio of 29.28. The Company's shares have gained 7.32% in the last one month and 22.98% in the previous three months. The stock is trading 5.90% above its 50-day moving average and 11.19% above its 200-day moving average. Moreover, shares of Jazz Pharmaceuticals have an RSI of 59.81. The company is headquartered in Dublin, Ireland. Register for free on ActiveWallSt.com and access the latest research on JAZZ at:

http://www.activewallst.com/register/

On Monday, shares in California headquartered development stage biopharma Company, Puma Biotechnology Inc., recorded a trading volume of 852,048 shares, which was higher than their three months average volume of 776,630 shares. The stock ended the day 5.33% lower at $35.51. The Company's shares have surged 51.17% in the last one month. The stock is trading above its 50-day moving average by 14.81%. Furthermore, shares of Puma Biotechnology have an RSI of 57.53. Get free access to your trade alert on PBYI at:

http://www.activewallst.com/register/

--

Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: info@activewallst.com Phone number:  1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA